NCT00501709View on ClinicalTrials.gov

Prevention of Autoimmune Destruction and Rejection of Human Pancreatic Islets Following Transplantation for Insulin Dependent Diabetes Mellitus

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Type 1 Diabetes
Interventions
DRUG

Belatacept and Raptiva

immunosuppressant agent to prevent rejection in transplant recipients

Trial Locations (1)

94143

University of California, San Francisco, San Francisco

Sponsors
All Listed Sponsors
collaborator

Juvenile Diabetes Research Foundation

OTHER

lead

University of California, San Francisco

OTHER